Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA FY 2024 Budget Includes 10% Funding Boost, But No Movement On Diagnostics

Executive Summary

The FDA requested a 10% increase in budget authority for FY 2024, but diagnostic reform was left out of the proposal. 

You may also be interested in...



Diagnostics Reform Reintroduced in House

The VALID Act, which will hand diagnostics oversight to the US FDA, has been reintroduced in the House of Representatives after it failed twice last year in Congress.

Increase Access To MedTech: AdvaMed’s Priorities For The 118th Congress

AdvaMed’s Medical Innovation Agenda for the 118th Congress emphasizes increased access to medical devices, from reimbursement for breakthrough devices to boosting America’s start-ups to closing the care disparities for underserved communities.

So The Public Health Emergency Is Over. Now What?

In January, US President Joe Biden announced that the COVID-19 public health emergency will expire in May. Dr. David Feldman, chief medical officer at The Doctors Company, spoke to Medtech Insight about what the official end of the emergency means for average Americans.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel